New JAMA Study Confirms Treating Prostate Cancer Preferable to 'Watchful Waiting'
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 




 
  




New JAMA Study Confirms Treating Prostate Cancer Preferable to 'Watchful Waiting'

Patients Should Consider All Options, including Minimally Invasive Cryoablation

IRVINE, CA -- December 22, 2006 -- Endocare, Inc., an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that a large study published in the Journal of the American Medical Association (JAMA) this month confirms that men with early prostate cancer should seriously consider all prostate cancer treatment options before choosing "watchful waiting" as a disease management approach. "Watchful waiting" is a concept that suggests patients can wait to see how their disease progresses before undergoing any curative treatments such as surgery or radiation.

The JAMA study published December 13, 2006, consisted of 44,630 men between the ages of 65 and 80 and found that those patients who chose to treat their prostate cancer were 30 percent less likely to die than those who waited. This suggests that all patients with localized
disease regardless of age should consider definitive treatments rather than "watchful waiting." It is estimated that approximately 30, 000 of the more than 225,000 men who are diagnosed with prostate cancer annually choose to wait rather than undergo treatment.

Endocare President, Chairman and CEO Craig T. Davenport noted, "This study offers further scientific evidence that 'watchful waiting' may not be the best option for many patients, particularly when there are effective, minimally invasive treatments like cryoablation available. Based on the results of the study, 'watchful waiting' patients should consider some kind of treatment. We believe cryoablation is an excellent option for many patients given its proven, long-term cancer control rate, low morbidity, and typically fast recovery time.
Additionally, we believe cryoablation is a particularly good option for 'watchful waiting' patients who are not able to tolerate surgery or radiation, or for men with very small amounts of cancer in their prostate."

Cryoablation involves non surgical freezing and destroying of the cancerous tumors using an Endocare Cryocare® System. Recently published 10-year data demonstrated that cryoablation is a viable, effective, safe, durable and many times preferable treatment option
for prostate cancer.

SOURCE: Endocare, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities